Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma
Craig H. Moskowitz(University of Miami), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), David B. Agus(California State University Los Angeles), Ariela Noy(Memorial Sloan Kettering Cancer Center), Barrett H. Childs(Florida Hospital Cancer Institute), Richard C. Frank(Memorial Sloan Kettering Cancer Center), Stephen D. Nimer(University of Miami), Eric Hedrick(Florida Hospital Cancer Institute), Nancy Coady-Lyons(Memorial Sloan Kettering Cancer Center), Joseph G. Jurcic(Memorial Sloan Kettering Cancer Center), Sonia Hunte(Memorial Sloan Kettering Cancer Center), André Goy(Hackensack University Medical Center), Jill R. Glassman, Joseph R. Bertino(Rutgers, The State University of New Jersey), James P. O’Brien(Memorial Sloan Kettering Cancer Center), Diane C. Louie(Memorial Sloan Kettering Cancer Center), David Straus(Memorial Sloan Kettering Cancer Center), Daniel A. Filippa(Memorial Sloan Kettering Cancer Center), Carol S. Portlock(Memorial Sloan Kettering Cancer Center), Joachim Yahalom(Unknown)
Cited by 303
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k